| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: = 99.43%
| ln Vitro |
Splenic lymphocytes isolated from IRBP (1-20), human-immunized mice showed specific proliferative responses upon in vitro restimulation with the peptide. In IFN-γ-deficient mice, the proliferation rate (assessed by ³H-thymidine incorporation) of lymphocytes stimulated with IRBP (1-20), human was 30% lower than that stimulated with full-length IRBP [1]
In H-2b haplotype mice, IRBP (1-20), human induced dose-dependent lymphocyte proliferation, with a proliferation index 3.5-fold higher than the irrelevant peptide control at 10 μg/mL [2] |
|---|---|
| ln Vivo |
Human TFA produces EAU in IRBP (1–20)[2]. 21 days following immunization, lymph node and splenocytes were harvested, and the proper antigens were used to activate them in culture in order to assess proliferation and cytokine responses. In response to this peptide, human TFA cells from C57BL/6 and 129/J mice inoculated with IRBP (1–20) multiplied [2].
In IFN-γ-deficient (IFN-γ⁻/⁻) mice, immunization with IRBP (1-20), human induced experimental autoimmune uveoretinitis (EAU) with an incidence of 40%, compared to 80% incidence induced by full-length IRBP. Pathological examination revealed milder retinal inflammation, less photoreceptor cell damage, and fewer inflammatory cell infiltrates in the IRBP (1-20), human-treated group [1] In H-2b haplotype mice (C57BL/6 and B10.A(4R)), IRBP (1-20), human induced EAU with 100% incidence. The average inflammatory score was 3.0 (on a 0-4 scale), characterized by severe retinal-choroidal inflammation, vascular perivasculitis, and photoreceptor layer destruction [2] |
| Cell Assay |
For lymphocyte proliferation assay in IFN-γ⁻/⁻ mice, spleens were collected 21 days after immunization, and single-cell suspensions were prepared. Lymphocytes were seeded in culture plates and stimulated with IRBP (1-20), human at a final concentration of 10 μg/mL. After 72 hours of incubation, ³H-thymidine was added, and incubation continued for another 18 hours. Radioactivity was measured to quantify lymphocyte proliferation [1]
In H-2b haplotype mice, splenic lymphocytes were isolated and cultured with serial concentrations of IRBP (1-20), human (1, 5, 10 μg/mL) for 48-72 hours. Lymphocyte proliferation was assessed by MTT assay, and the proliferation index was calculated by comparing absorbance with the unstimulated control group [2] |
| Animal Protocol |
Animal/Disease Models: C57BL/6 (H-2bb[2]
Doses: 200, 300 μg Route of Administration: 1 hour; Results after 21 days: C57BL/6 (H-2bb) also developed disease, although the mean score was lower than C57BL/6. For IFN-γ⁻/⁻ mice experiment, 6-8-week-old IFN-γ⁻/⁻ mice were randomly divided into three groups (n=10 per group). The experimental group was subcutaneously injected with 200 μg IRBP (1-20), human emulsified with complete Freund's adjuvant (CFA) containing mycobacteria. The positive control group received full-length IRBP, and the negative control group received CFA alone. Ocular symptoms were observed on days 14 and 21 post-immunization. Mice were sacrificed on day 21, and eyeballs were collected for fixation, embedding, sectioning, and HE staining to evaluate EAU pathological scores [1] For H-2b haplotype mice experiment, 6-8-week-old C57BL/6 and B10.A(4R) mice were divided into experimental and control groups (n=8 per group). The experimental group was subcutaneously injected with 50 μg IRBP (1-20), human emulsified with CFA. The control group received CFA or an irrelevant peptide. Ocular inflammation (iris hyperemia, vitreous opacity) was monitored weekly. On day 21, mice were euthanized for eyeball pathological analysis and splenic lymphocyte isolation [2] |
| References |
|
| Additional Infomation |
The human retinal interstitial retinoic acid-binding protein (IRBP) (1-20) fragment is a polypeptide fragment consisting of 1-20 amino acids from the N-terminus of human retinal interstitial retinoic acid-binding protein (IRBP) [1][2]. It is a pathogenic epitope that can induce experimental autoimmune uveitis (EAU) in H-2b haplotype mice and mediate ocular autoimmunity through specific T cell responses [2]. Compared with the full-length IRBP, the human retinal interstitial retinoic acid-binding protein (IRBP) (1-20) has a weaker uveitis-inducing potential in IFN-γ⁻/⁻ mice, suggesting that interferon-γ is crucial for the immunopathological response induced by this fragment [1]. EAU is a widely used animal model for studying human autoimmune uveitis, while the human retinal interstitial retinoic acid-binding protein (IRBP) (1-20) fragment is an important tool for studying the pathogenesis of autoimmune eye diseases [1][2].
|
| Molecular Formula |
C101H164N24O28S
|
|---|---|
| Molecular Weight |
2194.59188365936
|
| Exact Mass |
2180.174
|
| CAS # |
298202-25-2
|
| Related CAS # |
IRBP (1-20), human TFA
|
| PubChem CID |
170907461
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.6
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
69
|
| Heavy Atom Count |
153
|
| Complexity |
4660
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]4CCCN4C(=O)CN
|
| InChi Key |
SZDZCOAPFHTFJS-YPHDJVENSA-N
|
| InChi Code |
InChI=1S/C100H162N24O28S/c1-17-60(83(134)111-65(38-51(4)5)88(139)116-71(44-78(129)130)93(144)109-62(32-36-153-16)84(135)106-56(14)82(133)108-61(27-21-22-33-101)85(136)121-80(55(12)13)97(148)117-68(41-54(10)11)89(140)112-67(40-53(8)9)90(141)119-72(100(151)152)45-79(131)132)107-86(137)64(37-50(2)3)114-94(145)73(48-125)120-95(146)75-29-24-35-124(75)99(150)63(30-31-76(103)127)110-91(142)69(42-58-25-19-18-20-26-58)115-87(138)66(39-52(6)7)113-92(143)70(43-59-47-104-49-105-59)118-98(149)81(57(15)126)122-96(147)74-28-23-34-123(74)77(128)46-102/h18-20,25-26,47,49-57,60-75,80-81,125-126H,17,21-24,27-46,48,101-102H2,1-16H3,(H2,103,127)(H,104,105)(H,106,135)(H,107,137)(H,108,133)(H,109,144)(H,110,142)(H,111,134)(H,112,140)(H,113,143)(H,114,145)(H,115,138)(H,116,139)(H,117,148)(H,118,149)(H,119,141)(H,120,146)(H,121,136)(H,122,147)(H,129,130)(H,131,132)(H,151,152)/t56-,57+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,80-,81-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~45.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (1.14 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4557 mL | 2.2783 mL | 4.5567 mL | |
| 5 mM | 0.0911 mL | 0.4557 mL | 0.9113 mL | |
| 10 mM | 0.0456 mL | 0.2278 mL | 0.4557 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA